Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuoyan Liu

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 28, 2026
Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified managementChang Yuan, Chunji Chen, Zhichao Liu, et al.
Journal of the National Cancer Center|July 22, 2024
Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort studyYousheng Mao, Shugeng Gao, Yin Li, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|January 25, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in ChinaChunji Chen, Chang Yuan, Zhichao Liu, et al.
Nature Communications|November 3, 2025
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)Peiyuan Wang, Yujie Chen, Feng Wang, et al.
Nature Medicine|July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trialJianjun Qin, Liyan Xue, Anlin Hao, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 28, 2026
Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified managementChang Yuan, Chunji Chen, Zhichao Liu, et al.
Journal of the National Cancer Center|July 22, 2024
Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort studyYousheng Mao, Shugeng Gao, Yin Li, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|January 25, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in ChinaChunji Chen, Chang Yuan, Zhichao Liu, et al.
Nature Communications|November 3, 2025
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)Peiyuan Wang, Yujie Chen, Feng Wang, et al.
Nature Medicine|July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trialJianjun Qin, Liyan Xue, Anlin Hao, et al.
Pageof 4